Valuation: Steminent Biotherapeutics Inc.

Market Cap 5.26B 163M 142M 132M 121M 229M 15.56B 232M 1.55B 610M 7.75B 612M 599M 25.98B P/E 2024
-8.1x
P/E 2025 -20.4x
Enterprise Value 4.84B 150M 130M 121M 111M 210M 14.3B 213M 1.43B 561M 7.12B 563M 550M 23.88B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
58.85%
Yield 2024 *
-
Yield 2025 -
1 day+13.02%
1 week+1.80%
1 month+3.81%
3 months+0.51%
6 months+3.40%
Current year+31.45%
1 week 68
Extreme 68
82.8
1 month 67.1
Extreme 67.1
84.2
Current year 51.4
Extreme 51.4
95.6
1 year 26.05
Extreme 26.05
95.6
3 years 15.25
Extreme 15.25
95.6
5 years 15.25
Extreme 15.25
95.6
10 years 15.25
Extreme 15.25
95.6
Manager TitleAgeSince
Chief Executive Officer - 26/11/2018
Director of Finance/CFO - 15/09/2021
Investor Relations Contact - 01/10/2023
Director TitleAgeSince
Director/Board Member 54 08/12/2021
Director/Board Member - 15/09/2020
Chairman - 26/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
+13.02%+1.80%+183.66% - 163M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -0.05%+0.85%+75.66%+89.14% 25.06B
Weighted average by Cap. -1.59%+2.03%+79.85%+108.61%

Financials

2024 2025
Net sales - -
Net income -159M -4.92M -4.27M -3.98M -3.65M -6.9M -469M -7M -46.89M -18.4M -234M -18.46M -18.06M -783M -174M -5.39M -4.68M -4.36M -4M -7.56M -514M -7.68M -51.4M -20.17M -256M -20.24M -19.8M -859M
Net Debt -153M -4.74M -4.12M -3.84M -3.52M -6.66M -453M -6.76M -45.25M -17.76M -225M -17.82M -17.43M -756M -426M -13.19M -11.46M -10.67M -9.8M -18.5M -1.26B -18.78M -126M -49.36M -627M -49.52M -48.43M -2.1B
Logo Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.
Employees
-
Date Price Change Volume
31/07/26 NT$79.00 +13.02% 567,524
30/07/26 NT$69.90 -9.46% 272,581
29/07/26 NT$77.20 -0.64% 554,195
28/07/26 NT$77.70 -2.63% 489,519
27/07/26 NT$79.80 +2.84% 350,140
  1. Stock Market
  2. Stocks
  3. 7729 Stock